SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2021-12-01 Epub Date: 2021-10-30 DOI:10.1177/17246008211042899

Dandan Yuan, Jian Wang, Mingyu Yan, Yaohui Xu

{"title":"SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis.","authors":"Dandan Yuan, Jian Wang, Mingyu Yan, Yaohui Xu","doi":"10.1177/17246008211042899","DOIUrl":null,"url":null,"abstract":"Background: Sex determining region Y-box 2 (SOX2) has been reported as a potential therapeutic target for cancer. However, the role of SOX2 in cervical cancer remains largely undetermined. This study was performed to evaluate the correlation of SOX2 with clinical characteristics and prognosis in cervical cancer.Methods: Multiple databases were systematically searched for eligible publications. The combined odds ratios (ORs) or hazard ratios (HRs) with the corresponding 95% confidence intervals (CIs) were used to assess the effect sizes.Results: A total of 17 studies with 1906 participants were identified. SOX2 expression was higher in cervical cancer than in the normal control group (OR = 10.83, 95% CI = 6.64-17.67, P < 0.001), while no significant difference was observed between cervical cancer and cervical intraepithelial neoplasia. SOX2 expression was not associated with age, tumor stage, and lymph node metastasis, but was correlated with tumor grade (grade 2-3 vs. grade 1: OR = 4.59, 95% CI = 2.76-7.62, P < 0.001) and tumor size (≥4 cm vs. ≤4 cm: OR = 1.66, 95% CI = 1.05-2.60, P = 0.028). Based on multivariate Cox analysis, SOX2 expression was not correlated with overall survival, but was closely associated with poor recurrence-free survival (HR = 5.83, 95% CI = 1.35-25.16, P = 0.018) and progress-free survival HR = 2.29, 95% CI = 1.01-5.19, P = 0.046).Conclusion: SOX2 may serve as a novel prognostic factor and a promising molecular target for cervical cancer.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 4","pages":"45-53"},"PeriodicalIF":2.3000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17246008211042899","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Background: Sex determining region Y-box 2 (SOX2) has been reported as a potential therapeutic target for cancer. However, the role of SOX2 in cervical cancer remains largely undetermined. This study was performed to evaluate the correlation of SOX2 with clinical characteristics and prognosis in cervical cancer.

Methods: Multiple databases were systematically searched for eligible publications. The combined odds ratios (ORs) or hazard ratios (HRs) with the corresponding 95% confidence intervals (CIs) were used to assess the effect sizes.

Results: A total of 17 studies with 1906 participants were identified. SOX2 expression was higher in cervical cancer than in the normal control group (OR = 10.83, 95% CI = 6.64-17.67, P < 0.001), while no significant difference was observed between cervical cancer and cervical intraepithelial neoplasia. SOX2 expression was not associated with age, tumor stage, and lymph node metastasis, but was correlated with tumor grade (grade 2-3 vs. grade 1: OR = 4.59, 95% CI = 2.76-7.62, P < 0.001) and tumor size (≥4 cm vs. ≤4 cm: OR = 1.66, 95% CI = 1.05-2.60, P = 0.028). Based on multivariate Cox analysis, SOX2 expression was not correlated with overall survival, but was closely associated with poor recurrence-free survival (HR = 5.83, 95% CI = 1.35-25.16, P = 0.018) and progress-free survival HR = 2.29, 95% CI = 1.01-5.19, P = 0.046).

Conclusion: SOX2 may serve as a novel prognostic factor and a promising molecular target for cervical cancer.

查看原文本刊更多论文

SOX2作为宫颈癌预后标志物和潜在分子靶点:一项荟萃分析

背景:性别决定区Y-box 2 (SOX2)已被报道为癌症的潜在治疗靶点。然而，SOX2在宫颈癌中的作用在很大程度上仍未确定。本研究旨在探讨SOX2与宫颈癌临床特征及预后的相关性。方法:系统检索多个数据库中符合条件的出版物。采用联合优势比(or)或风险比(hr)及其相应的95%置信区间(ci)来评估效应大小。结果:共有17项研究，1906名参与者被确定。SOX2在宫颈癌中的表达高于正常对照组(OR = 10.83, 95% CI = 6.64 ~ 17.67, P < 0.001)，而在宫颈癌和宫颈上皮内瘤变组中表达差异无统计学意义。SOX2表达与年龄、肿瘤分期和淋巴结转移无关，但与肿瘤分级(2-3级vs. 1级:OR = 4.59, 95% CI = 2.76 ~ 7.62, P < 0.001)和肿瘤大小(≥4 cm vs.≤4 cm: OR = 1.66, 95% CI = 1.05 ~ 2.60, P = 0.028)相关。多因素Cox分析显示，SOX2表达与总生存率无相关性，但与不良无复发生存率(HR = 5.83, 95% CI = 1.35 ~ 25.16, P = 0.018)和无进展生存率(HR = 2.29, 95% CI = 1.01 ~ 5.19, P = 0.046)密切相关。结论:SOX2可能是一种新的宫颈癌预后因子和有前景的分子靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.